Epstein-Barr Virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy

Transplantation

Volumn 77, Issue 1, 2004, Pages 76-84

  Clave, Emmanuel ^a   Agbalika, Félix ^b   Bajzik, Véronique ^a   De Latour, Régis Peffault ^a   Trillard, Mélanie ^a   Rabian, Claire ^a   Scieux, Catherine ^b   Devergie, Agnès ^b   Socié, Gérard ^b   Ribaud, Patricia ^b   Adès, Lionel ^b   Ferry, Christèle ^b   Gluckman, Eliane ^b   Charron, Dominique ^a   Esperou, Hélène ^b   Toubert, Antoine ^a   Moins Teisserenc, Hélène ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HLA A ANTIGEN; METHOTREXATE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FETAL BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; KINETICS; LIVING DONORS; MIDDLE AGED; POPULATION SURVEILLANCE; POSTOPERATIVE PERIOD; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 9144236279     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000093997.83754.2B     Document Type: Article

References (30)

1. Borysiewicz LK, Graham S, Hickling JK, et al. Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol 1988; 18(2): 269.
2. Khatri VP, Baiocchi RA, Peng R, et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 1999; 163(1): 500.
3. Rickinson AB, Callan MF, Annels NE. T-cell memory: lessons from Epstein-Barr virus infection in man. Philos Trans R Soc Lond B Biol Sci 2000; 355(1395): 391.
4. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86(7): 2815.
5. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97(5): 1165.
6. Hebart H, Kanz L, Jahn G, et al. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs 1998; 55(1): 59.
7. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84(8): 2457.
8. Heslop H, Rooney C, Brenner M, et al. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther 2000; 11(10): 1465.
9. O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195.
10. Ades L, Guardiola P, Socie G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev 2002; 16(2): 135.
11. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98(4): 972.
12. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807.
13. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99(12): 4364.
14. Steven NM, Annels NE, Kumar A, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997; 185(9): 1605.
15. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274(5284): 94.
16. McMichael AJ, O'Callaghan CA. A new look at T cells. J Exp Med 1998; 187(9): 1367.
17. Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162(3): 1827.
18. Dunbar PR, Ogg GS, Chen J, et al. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998; 8(7): 413.
19. Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002; 2: 263.
20. Marshall DR, Turner SJ, Belz GT, et al. Measuring the diaspora for virus-specific CD8+ T cells. Proc Natl Acad Sci U S A 2001; 98(11): 6313.
21. Koehne G, Smith KM, Ferguson TL, et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002; 99(5): 1730.
22. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37(1): 132.
23. Gault E, Michel Y, Dehee A, Belabani C, et al. Quantification of human cytomegalovirus DNA by real-time PCR. J Clin Microbiol 2001; 39(2): 772.
24. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330(17): 1185.
25. Saulquin X, Ibisch C, Peyrat MA, et al. A global appraisal of immunodominant CD8 T cell responses to Epstein- Barr virus and cytomegalovirus by bulk screening. Eur J Immunol 2000; 30(9): 2531.
26. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345(8941): 9.
27. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94(7): 2208.
28. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96(13): 4055.
29. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232.
30. Barker JN, Martin PL, Coad JE, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001; 7(7): 395.